MarketCap
Facebook
X
TelegramAnnual report 2022
added 08-30-2022
Genetic Technologies Limited Balance Sheet 2011-2026 | GENE
Annual Balance Sheet Genetic Technologies Limited
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-11.1 M | -20.7 M | -13.9 M | -2.13 M | -5.49 M | -11 M | -11.2 M | -18.3 M | -326 K | -1.72 M | -8.88 M | -5.04 M |
Long Term Debt |
388 K | 24.4 K | 52.3 K | - | - | - | - | - | 2.5 M | - | - | - |
Long Term Debt Current |
264 K | 180 K | 241 K | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
559 K | 33.3 K | 243 K | 809 | 3.39 K | 64 K | 74.3 K | 25.3 K | 2.58 M | 96.2 K | 109 K | 82.7 K |
Total Liabilities |
4.37 M | 1.44 M | 1.64 M | 1.49 M | 1.45 M | 1.53 M | 1.41 M | 1.76 M | 4.9 M | 2.56 M | 2.04 M | 2.11 M |
Deferred Revenue |
- | - | - | - | - | - | - | 77.3 K | 153 K | 321 K | 267 K | 164 K |
Retained Earnings |
-150 M | -143 M | -136 M | -130 M | -123 M | -118 M | -109 M | -101 M | -92.2 M | -82 M | -72.8 M | -67.5 M |
Total Assets |
20.8 M | 23 M | 15.6 M | 3.27 M | 6.17 M | 12.1 M | 13.3 M | 20.7 M | 6.73 M | 8.32 M | 16.4 M | 8.92 M |
Cash and Cash Equivalents |
11.7 M | 20.9 M | 14.2 M | 2.13 M | 5.49 M | 11 M | - | 18.3 M | - | - | - | - |
Book Value |
16.4 M | 21.5 M | 14 M | 1.77 M | 4.71 M | 10.6 M | 11.9 M | 19 M | 1.83 M | 5.76 M | 14.4 M | 6.81 M |
Total Shareholders Equity |
16.4 M | 21.5 M | 14 M | 1.76 M | 4.71 M | 10.6 M | 11.9 M | - | - | - | - | - |
All numbers in AUD currency
Quarterly Balance Sheet Genetic Technologies Limited
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | 388 K | - | - | - | 24.4 K | - | - | - | 189 K | - | 137 K | - | 251 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | 559 K | - | - | - | 33.3 K | - | - | - | 243 K | - | 138 K | - | 809 | - | - | - | 3.39 K | - | - | - | 64 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
- | - | 4.37 M | - | - | - | 1.44 M | - | - | - | 1.64 M | - | 1.48 M | - | 1.49 M | - | - | - | 1.45 M | - | - | - | 1.53 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
- | - | -150 M | - | - | - | -143 M | - | - | - | -136 M | - | -132 M | - | -130 M | - | - | - | -123 M | - | - | - | -118 M | - | - | - | -109 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
- | - | 20.8 M | - | - | - | 23 M | - | - | - | 15.6 M | - | 4.34 M | - | 3.27 M | - | - | - | 6.17 M | - | - | - | 12.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
- | - | 11.7 M | - | - | - | 20.9 M | - | - | - | 14.2 M | - | 3.28 M | - | 2.13 M | - | 3.23 M | - | 5.49 M | - | - | - | 11 M | - | - | - | 11.2 M | - | - | - | 11.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
- | - | 16.4 M | - | - | - | 21.5 M | - | - | - | 14 M | - | 2.86 M | - | 1.77 M | - | - | - | 4.71 M | - | - | - | 10.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
- | - | 16.4 M | - | - | - | 21.5 M | - | - | - | 14 M | - | 2.86 M | - | 1.77 M | - | 3.02 M | - | 4.71 M | - | - | - | 10.6 M | - | - | - | 11.9 M | - | - | - | 19 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in AUD currency
Balance Sheet is a fundamental financial report of Genetic Technologies Limited, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Diagnostics research
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Akumin
AKU
|
- | -17.87 % | $ 25.9 M |  Canada |
|
Centogene N.V.
CNTG
|
- | -6.23 % | $ 30.6 M |  Germany |
 |
Accelerate Diagnostics
AXDX
|
- | -61.36 % | $ 2.46 M |  USA |
 |
Brainsway Ltd.
BWAY
|
$ 19.02 | 0.21 % | $ 99.4 M |  Israel |
 |
Biocept
BIOC
|
- | -13.05 % | $ 7.29 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
$ 20.15 | -2.3 % | $ 217 M |  China |
 |
Chembio Diagnostics
CEMI
|
- | 0.22 % | $ 16.8 M | USA |
 |
Co-Diagnostics
CODX
|
$ 0.17 | -6.7 % | $ 4.99 M | USA |
 |
Castle Biosciences
CSTL
|
$ 38.9 | -1.04 % | $ 1.08 B | USA |
 |
BioNano Genomics
BNGO
|
$ 1.53 | 2.0 % | $ 1.94 M | USA |
 |
Danaher Corporation
DHR
|
$ 228.92 | -0.76 % | $ 167 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
- | - | $ 562 M |  Britain |
 |
DexCom
DXCM
|
$ 66.37 | -1.03 % | $ 25.6 B | USA |
 |
Enzo Biochem
ENZ
|
- | -8.98 % | $ 14.8 K | USA |
 |
DermTech
DMTK
|
- | -11.32 % | $ 2.94 M | USA |
 |
DarioHealth Corp.
DRIO
|
$ 11.38 | 6.36 % | $ 323 M | Israel |
 |
Exact Sciences Corporation
EXAS
|
$ 101.56 | -0.33 % | $ 18.8 B | USA |
 |
Fulgent Genetics
FLGT
|
$ 26.27 | -0.83 % | $ 794 M | USA |
 |
Global Cord Blood Corporation
CO
|
- | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
- | 1.08 % | $ 308 M | USA |
 |
Genetron Holdings Limited
GTH
|
- | 0.12 % | $ 80.1 M | China |
 |
PRA Health Sciences, Inc.
PRAH
|
- | - | $ 10.7 B | USA |
 |
Heska Corporation
HSKA
|
- | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
- | -20.0 % | $ 1.06 M | USA |
 |
CareDx, Inc
CDNA
|
$ 18.84 | -1.21 % | $ 1.01 B | USA |
 |
Celcuity
CELC
|
$ 99.74 | -0.18 % | $ 3.93 B | USA |
 |
IQVIA Holdings
IQV
|
$ 225.41 | -1.0 % | $ 40.9 B | USA |
 |
Anixa Biosciences
ANIX
|
$ 3.12 | - | $ 99.5 K | USA |
 |
Guardant Health
GH
|
$ 102.14 | 1.53 % | $ 12.5 B | USA |
 |
Aspira Women's Health
AWH
|
- | -6.19 % | $ 10.5 M | USA |
 |
Motus GI Holdings
MOTS
|
- | -34.28 % | $ 263 K | Israel |
 |
Myriad Genetics
MYGN
|
$ 6.15 | -0.32 % | $ 557 M | USA |
 |
Illumina
ILMN
|
$ 131.16 | -1.2 % | $ 20.9 B | USA |
 |
Charles River Laboratories International
CRL
|
$ 199.48 | -1.24 % | $ 10.2 B | USA |
 |
ENDRA Life Sciences
NDRA
|
$ 4.53 | -4.83 % | $ 2.43 M | USA |
 |
NeoGenomics
NEO
|
$ 11.76 | -3.84 % | $ 1.49 B | USA |
 |
National Research Corporation
NRC
|
$ 18.77 | 0.64 % | $ 461 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
$ 173.53 | -1.12 % | $ 19.3 B | USA |
|
Biodesix
BDSX
|
$ 6.8 | 1.19 % | $ 882 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
$ 250.88 | -0.87 % | $ 21 B | USA |
 |
ICON Public Limited Company
ICLR
|
$ 182.22 | -0.43 % | $ 15 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
$ 676.53 | -0.85 % | $ 55.8 B | USA |
 |
Lantheus Holdings
LNTH
|
$ 66.55 | -0.91 % | $ 4.61 B | USA |
 |
Mettler-Toledo International
MTD
|
$ 1 394.19 | -1.42 % | $ 29.6 B |  Schweiz |
 |
Agilent Technologies
A
|
$ 136.07 | -1.13 % | $ 41.4 B | USA |
 |
Organovo Holdings
ONVO
|
- | -2.3 % | $ 19.4 M | USA |
 |
Biomerica
BMRA
|
$ 2.52 | 2.86 % | $ 5.79 M | USA |
 |
OpGen
OPGN
|
- | -16.95 % | $ 1.54 M | USA |
 |
OPKO Health
OPK
|
$ 1.26 | -3.08 % | $ 874 M | USA |